AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
Amgen (NASDAQ:AMGN) announced a webcast for the investment community at 8:00 a.m. ET on December 12, 2022, following its acquisition of Horizon Therapeutics. CEO Robert A. Bradway and the executive team will participate in the call, which will be accessible to media and the public. The event will be archived for 90 days on Amgen’s website. This acquisition highlights Amgen's commitment to addressing serious medical needs and expanding its innovative pipeline of therapeutics.
- Strategic acquisition of Horizon Therapeutics enhances Amgen's product pipeline.
- Webcast indicates transparency and engagement with investors.
- None.
THOUSAND OAKS, Calif., Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022. Robert A. Bradway, chairman and chief executive officer, along with members of the executive team, will participate.
The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
The directors of Amgen accept responsibility for the information contained in this press release. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this press release is in accordance with the facts and does not omit anything likely to affect the import of such information.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.
For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.
CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974 (media)
Arvind Sood, 805-447-1060 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-host-webcast-investor-call-following-announced-acquisition-of-horizon-therapeutics-301699964.html
SOURCE Amgen
FAQ
What is the purpose of Amgen's acquisition of Horizon Therapeutics?
When will Amgen host the investor call regarding the Horizon Therapeutics acquisition?
Who will participate in Amgen's investor call for the Horizon Therapeutics acquisition?
How can I access the Amgen webcast on the acquisition of Horizon Therapeutics?
What impact does the Horizon Therapeutics acquisition have on Amgen's business?
